Back to School: How biopharma can reboot drug development. Access exclusive analysis here

British Bio, Vernalis Group deal

BBG will merge with VER in a stock deal in which BBG shareholders will own 47% of the new company and VER shareholders will own 53%. BBG

Read the full 275 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE